Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History CLSD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics CLSD

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Clearside Biomedical Inc

CLSD
Current price
0.84 USD -0.004 USD (-0.48%)
Last closed 0.83 USD
ISIN US1850631045
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 68 033 792 USD
Yield for 12 month -27.30 %
1Y
3Y
5Y
10Y
15Y
CLSD
21.11.2021 - 28.11.2021

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. The company offers XIPERE, a triamcinolone acetonide injectable suspension for the treatment of macular edema associated with uveitis. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which has completed Phase 2 clinical trial to treat wet AMD. The company has a collaboration with bausch + lomb ireland limited, Arctic Vision (Hong Kong) Limited, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences, Inc. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia. Address: 900 North Point Parkway, Alpharetta, GA, United States, 30005

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

5.43 USD

P/E Ratio

Dividend Yield

Financials CLSD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures CLSD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+1 664 000 USD

Last Year

+8 226 000 USD

Current Quarter

+2 330 000 USD

Last Quarter

+306 000 USD

Current Year

+1 515 000 USD

Last Year

+7 871 000 USD

Current Quarter

+2 082 000 USD

Last Quarter

+157 000 USD
EBITDA -25 595 000 USD
Operating Margin TTM -223.39 %
Price to Earnings
Return On Assets TTM -54.08 %
PEG Ratio
Return On Equity TTM -1 310.02 %
Wall Street Target Price 5.43 USD
Revenue TTM 3 764 000 USD
Book Value -0.59 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 913.00 %
Dividend Yield
Gross Profit TTM 3 367 000 USD
Earnings per share -0.41 USD
Diluted Eps TTM -0.41 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY
Profit Margin

Stock Valuation CLSD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 14.71
Price Sales TTM 18.07
Enterprise Value EBITDA -2.84
Price Book MRQ 3.93

Technical Indicators CLSD

For 52 Weeks

0.70 USD 1.65 USD
50 Day MA 0.83 USD
Shares Short Prior Month 348 964
200 Day MA 0.97 USD
Short Ratio 0.92
Shares Short 396 961
Short Percent 0.46 %